Supernus Pharmaceuticals Inc. (SUPN)
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.42 per share a year ago.
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.75 per share a year ago.
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus: Outlook For 2026 Positive, Upholding Buy Rating
Supernus remains a Buy, with shares up >50% since mid-2025 and ~25% upside projected for 2026. Qelbree drives growth, with 2026 net sales expected to exceed $450m; patent expirations are being offset by pipeline and acquisitions. The Sage Therapeutics acquisition adds near-term revenue and pipeline depth, though pipeline maturity limits major new launches before 2027.
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. ( SUPN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Jack Khattar - Founder, President, CEO, Secretary & Director Timothy Dec - Senior VP & CFO Conference Call Participants Peter Vozzo - Westwicke Partners, LLC Lin Tsai - Jefferies LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division David Amsellem - Piper Sandler & Co., Research Division Pavan Patel - BofA Securities, Research Division Stacy Ku - TD Cowen, Research Division Presentation Operator " Jack Khattar Founder, President, CEO, Secretary & Director " Timothy Dec Senior VP & CFO " Peter Vozzo Westwicke Partners, LLC " Lin Tsai Jefferies LLC, Research Division " Jefferies LLC, Research Division Annabel Samimy Stifel, Nicolaus & Company, Incorporated, Research Division " Stifel, Nicolaus & Company, Incorporated, Research Division David Amsellem Piper Sandler & Co., Research Division " Piper Sandler & Co., Research Division Pavan Patel BofA Securities, Research Division " BofA Securities, Research Division Stacy Ku TD Cowen, Research Division " TD Cowen, Research Division Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
